A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Development of new Coumarin-based profluorescent substrates for human cytochrome P450 enzymes




TekijätJuvonen R., Ahinko M., Huuskonen J., Raunio H., Pentikäinen O.

KustantajaTaylor and Francis Ltd

Julkaisuvuosi2019

JournalXenobiotica

Tietokannassa oleva lehden nimiXenobiotica

Vuosikerta49

Numero9

Aloitussivu1015

Lopetussivu1024

Sivujen määrä10

ISSN0049-8254

eISSN1366-5928

DOIhttps://doi.org/10.1080/00498254.2018.1530399


Tiivistelmä
  1. Cytochrome
    P450 (CYP) enzymes constitute an essential xenobiotic metabolizing
    system that regulates the elimination of lipophilic compounds from the
    body. Convenient and affordable assays for CYP enzymes are important for
    assessing these metabolic pathways.

  2. In
    this study, 10 novel profluorescent coumarin derivatives with various
    substitutions at carbons 3, 6 and 7 were developed. Molecular modeling
    indicated that 3-phenylcoumarin offers an excellent scaffold for the
    development of selective substrate compounds for various human CYP
    forms, as they could be metabolized to fluorescent 7-hydroxycoumarin
    derivatives. Oxidation of profluorescent coumarin derivatives to
    fluorescent metabolites by 13 important human liver
    xenobiotic-metabolizing CYP forms was determined by enzyme kinetic
    assays.

  3. Four of the coumarin derivatives
    were converted to fluorescent metabolites by CYP1 family enzymes, with
    6-methoxy-3-(4-trifluoromethylphenyl)coumarin being oxidized selectively
    by CYP1A2 in human liver microsomes. Another set of four compounds were
    metabolized by CYP2A6 and CYP1 enzymes.
    7-Methoxy-3-(3-methoxyphenyl)coumarin was oxidized efficiently by
    CYP2C19 and CYP2D6 in a non-selective fashion.

  4. The
    advantages of the novel substrates were (1) an excellent
    signal-to-background ratio, (2) selectivity for CYP1 forms, and (3)
    convenient multiwell plate measurement, allowing for precise
    determination of potential inhibitors of important human hepatic forms
    CYP1A2, CYP2C19 and CYP2D6.



Last updated on 2024-26-11 at 18:26